ValuEngine Lowers Dentsply Sirona (XRAY) to Strong Sell

ValuEngine downgraded shares of Dentsply Sirona (NASDAQ:XRAY) from a sell rating to a strong sell rating in a research note published on Tuesday.

A number of other equities analysts have also issued reports on the stock. BidaskClub lowered shares of Dentsply Sirona from a hold rating to a sell rating in a research report on Tuesday, January 23rd. Credit Suisse Group reduced their price target on shares of Dentsply Sirona from $73.00 to $69.00 and set an outperform rating for the company in a research report on Friday, March 2nd. HC Wainwright set a $63.00 price target on shares of Dentsply Sirona and gave the stock a hold rating in a research report on Monday, March 5th. Barrington Research reissued an outperform rating and set a $70.00 price target (down from $73.00) on shares of Dentsply Sirona in a research report on Monday, March 5th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Dentsply Sirona from $75.00 to $70.00 and set an overweight rating for the company in a research report on Monday, March 5th. Three research analysts have rated the stock with a sell rating, four have given a hold rating and nine have given a buy rating to the company. The company presently has a consensus rating of Hold and a consensus price target of $63.38.

Shares of Dentsply Sirona stock opened at $46.21 on Tuesday. The company has a market capitalization of $10.75 billion, a P/E ratio of 17.37, a P/E/G ratio of 2.38 and a beta of 1.26. The company has a quick ratio of 1.46, a current ratio of 2.23 and a debt-to-equity ratio of 0.25. Dentsply Sirona has a 52 week low of $44.21 and a 52 week high of $68.98.

Dentsply Sirona (NASDAQ:XRAY) last announced its quarterly earnings data on Sunday, May 6th. The medical instruments supplier reported $0.45 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.42 by $0.03. The firm had revenue of $956.10 million during the quarter, compared to analyst estimates of $942.20 million. Dentsply Sirona had a negative net margin of 38.32% and a positive return on equity of 8.63%. Dentsply Sirona’s revenue was up 6.2% on a year-over-year basis. During the same period last year, the firm posted $0.49 EPS. analysts expect that Dentsply Sirona will post 2.58 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 13th. Shareholders of record on Friday, June 29th will be given a dividend of $0.0875 per share. This represents a $0.35 dividend on an annualized basis and a yield of 0.76%. The ex-dividend date of this dividend is Thursday, June 28th. Dentsply Sirona’s dividend payout ratio is presently 13.16%.

In other news, CEO Donald M. Jr. Casey bought 22,500 shares of the business’s stock in a transaction dated Wednesday, May 9th. The stock was purchased at an average cost of $44.52 per share, with a total value of $1,001,700.00. Following the acquisition, the chief executive officer now directly owns 92,408 shares in the company, valued at $4,114,004.16. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Nicholas W. Alexos bought 50,000 shares of the business’s stock in a transaction dated Wednesday, May 9th. The shares were purchased at an average cost of $44.71 per share, with a total value of $2,235,500.00. Following the completion of the acquisition, the chief financial officer now owns 25,411 shares in the company, valued at $1,136,125.81. The disclosure for this purchase can be found here. 1.93% of the stock is owned by insiders.

Several large investors have recently bought and sold shares of XRAY. Bank of Montreal Can increased its holdings in shares of Dentsply Sirona by 6.1% during the 4th quarter. Bank of Montreal Can now owns 211,583 shares of the medical instruments supplier’s stock valued at $13,929,000 after purchasing an additional 12,211 shares in the last quarter. National Pension Service increased its holdings in shares of Dentsply Sirona by 9.5% during the 4th quarter. National Pension Service now owns 251,674 shares of the medical instruments supplier’s stock valued at $16,568,000 after purchasing an additional 21,906 shares in the last quarter. Creative Planning increased its holdings in shares of Dentsply Sirona by 33.8% during the 4th quarter. Creative Planning now owns 14,758 shares of the medical instruments supplier’s stock valued at $971,000 after purchasing an additional 3,724 shares in the last quarter. Schwab Charles Investment Management Inc. increased its holdings in shares of Dentsply Sirona by 3.2% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 795,363 shares of the medical instruments supplier’s stock valued at $52,359,000 after purchasing an additional 24,585 shares in the last quarter. Finally, Oakbrook Investments LLC purchased a new position in shares of Dentsply Sirona during the 4th quarter valued at approximately $589,000. 93.59% of the stock is owned by hedge funds and other institutional investors.

Dentsply Sirona Company Profile

DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Dentsply Sirona (NASDAQ:XRAY)

Receive News & Ratings for Dentsply Sirona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dentsply Sirona and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply